{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"description":"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR","groups":[{"description":"Within 42 days after hematopoietic engraftment (both neutrophils and platelets) after autologous HSCT, patients receive initial treatment with IHC. Patients that do not have evidence of relapse or progressive disease may be treated every 8-12 weeks for up to 3 doses.\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Receive IHC\n\nIrradiated Allogeneic Cells: Correlative studies","id":"OG000","title":"Cohort I (Initial IHC Within 42 Days)"},{"description":"Patients with high-risk disease receive initial treatment with IHC within 70 days after hematopoietic engraftment (both neutrophils and platelets) after allogeneic HSCT. Patients being treated for relapsed disease may receive initial treatment with IHC any time after relapse is documented. Patients that do not have evidence of relapse or progressive disease may be treated every 8-12 weeks for up to 3 doses.\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Receive IHC\n\nIrradiated Allogeneic Cells: Correlative studies","id":"OG001","title":"Cohort II (Initial IHC Within 70 Days or After Relapse)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"no data was collected. Refers to the Cohort 1 Arm","reportingStatus":"POSTED","timeFrame":"Up to 8 weeks after last protocol treatment","title":"Number of Participants Who Received Irradiated Haploidentical Cells (IHC) With Disease Response","type":"PRIMARY","unitOfMeasure":"Participants"}